Crowell & Moring Releases Litigation Forecast 2022: What Corporate Counsel Need to Know for the Coming Year
Firm News | 3 min read | 01.12.22
Where Technology, Litigation, and IP Intersect
Washington — January 12, 2022: Crowell & Moring has published Litigation Forecast 2022: What Corporate Counsel Need to Know for the Coming Year. The tenth-annual Litigation Forecast focuses on the intersection of technology, litigation, and intellectual property, including significant changes to the Patent Trial and Appeal Board process, the impact of Google v. Oracle on copyright, new developments in the biopharma space, shifting FTC enforcement strategies, and more. The Litigation Forecast provides forward-looking insights from leading Crowell & Moring lawyers to help legal departments anticipate and respond to challenges that might arise in the year ahead.
The cover story, “When the Disruptors Get Disrupted,” explores the critical importance of IP litigation in the competitive landscape and how technology industry participants are going beyond patents and turning to a broader range of trade secrets, copyright, trademarks, and other IP rights to protect their inventions. Crowell & Moring partner Warrington Parker explores how emerging technologies—from NFTs to artificial intelligence—are opening new avenues of innovation and leading to novel types of litigation. And he examines how competitor-versus-competitor litigation is taking place against the background of Washington’s growing scrutiny of Big Tech companies.
“Over the past several years, technology litigation has exploded, and companies have helped propel this growth with an expansion in the ways in which they protect their technology-based IP,” said Philip T. Inglima, chair of Crowell & Moring. “In our Forecast this year, we examine the latest developments in technology, litigation, and IP in order to help our clients be more competitive, more nimble, and even more transformative as they navigate this changing landscape.”
In “The Changing Rules of the Road,” partner Vincent J. Galluzzo discusses the impact of two decisions that have reshaped basic processes at the USPTO’s PTAB, including the impact of the Supreme Court’s Arthrex Inc. v. Smith & Nephew Inc. decision, which has paved the way for a new inter partes review process, and an increase in discretionary denials of IPR proceedings stemming from the PTAB’s Apple v. Fintiv decision.
Articles in the Forecast include:
-
- Cover Story – The Intersection of Technology, Litigation, and IP – “When the Disruptors Get Disrupted”
- BioPharma – “The Calm Between the CRISPR Storms”
- Branding – “The FTC Flexes Its Muscles”
- Copyright/Software – “Fair Use: When Clarification Isn’t Necessarily Clear”
- International Trade Commission – “A Sledgehammer for Fighting Knockoffs”
- Jurisdictional Analysis – “Efficient Docket Management, Fewer Filings”
- PTAB Litigation – “The Changing Rules of the Road”
- Patent Cases – “An Open Door for MOT Patent Litigation”
- Trade Secrets – “Expect Claims to Keep Rising”
- Trademark – “Conflicting Decisions Raise Uncertainty”
All of the articles from the Forecast are available at https://www.crowell.com/en/services/topics/litigation-forecast. Follow the conversation on social media with #LitigationForecast.
https://www.crowell.com/en/services/topics/litigation-forecast
Insights
Firm News | 1 min read | 03.11.25
Crowell & Moring Represents Nuclear Energy Startup Atomic Alchemy in its Acquisition by Oklo
March 11, 2025: Oklo Inc. (NYSE: OKLO), an advanced nuclear technology company, announced on March 5, 2025 that it has closed the $25 million acquisition of Crowell client Atomic Alchemy Inc. (“Atomic Alchemy”), a leading innovator in radioisotope production. Oklo intends to use this strategic acquisition to establish a more reliable domestic supply chain for high-value radioisotopes critical to healthcare, research, and defense sectors and provides synergies to Oklo’s fuel recycling and nuclear energy businesses. Demand for radioisotopes is expected to increase significantly over the next decade, while global supply struggles to keep pace due to aging reactor infrastructure and a fragmented global supply chain, which at present is dominated by countries outside the United States. Atomic Alchemy intends to be a low-cost U.S. radioisotope producer that can provide a secure and domestic supply of radioisotopes to U.S. companies commercializing innovative radioisotope applications. With its proprietary VIPR® technology, Atomic Alchemy is building the first scalable production facility to provide a reliable, sustainable source of high-value radioisotopes. Using a vertically integrated model and fuel recycling, in partnership with Oklo, Atomic Alchemy is transforming isotope production to address global shortages, support critical applications, and strengthen national security. The core deal team included Samuel Holland Edwards, Jon O’Connell, Justin Lurie, and Ryan Flynn.
Firm News | 2 min read | 03.11.25
Daily Journal Honors Crowell & Moring Victory in University of California Case
Firm News | 2 min read | 03.11.25
Foreign Investment Watch Names Caroline Brown a Top Advisor 2025
Firm News | 2 min read | 03.07.25
Crowell & Moring Attorneys Honored With 2025 Burton Award for Distinguished Legal Writing